A Multiple Dose Escalation Study of ASKP1240 in Subjects with Moderate to Severe Plaque Psoriasis

Trial Identifier: 7163-CL-0107
Sponsor: Astellas Pharma Global Development Inc.
Collaborator:
Kyowa Hakko Kirin Company, Limited
Start Date: April 2012
Primary Completion Date: June 2014
Study Completion Date: January 2015
Condition: Psoriasis

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Australia, Queensland Brisbane, Queensland, Australia, 4102
Australia, Victoria Adelaide, Victoria, Australia, 5000
Australia, Victoria Richmond, Victoria, Australia, 3121
Australia, Western Australia Nedlands, Western Australia, Australia, 6009
CA, Newfoundland St. John's, Newfoundland, CA, A1C 2H5
Canada, Manitoba Winnipeg, Manitoba, Canada, R3C 0N2
Canada, New Brunswick Moncton, New Brunswick, Canada, E1C 8X3
Canada, Ontario Barrie, Ontario, Canada, L4M 6L2
Canada, Ontario Waterloo, Ontario, Canada, N2J 1C4
Canada, Quebec Montreal, Quebec, Canada, H2K 4L5
New Zealand Auckland, New Zealand, 1010
New Zealand Christchurch, New Zealand, 8011
New Zealand Tauranga, New Zealand, 3110
New Zealand Wellington, New Zealand, 6021